# ACNS0122

Source: https://onco.cc/trials/acns0122/  
OnCo record `acns0122` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ACNS0122 set the modern American standard for children with the more aggressive kind of germ cell tumour of the brain: chemotherapy first, surgery for anything left, then radiotherapy to the whole brain and spine, which cured about nine in ten and became the benchmark that later trials tried to match with less radiation.

## Summary

ACNS0122 was a Children's Oncology Group phase 2 study of 104 patients with newly diagnosed non-germinomatous germ cell tumours of the central nervous system. Induction was six cycles of carboplatin and etoposide alternating with ifosfamide and etoposide; patients with residual disease had second-look surgery, and those still not in complete response received high-dose thiotepa and etoposide with autologous stem cell rescue before craniospinal irradiation of 36 Gy with a boost to 54 Gy. The primary endpoint was the response rate to induction.

In the registry results 74 of 85 evaluable patients responded to induction chemotherapy. Three-year progression-free and overall survival were 92 and 94.1 percent, figures quoted as the benchmark in the successor trial ACNS1123, which tested reduced whole-ventricular radiotherapy against this standard. The corpus's germ cell tumour pages cite ACNS0122 for the chemotherapy-then-craniospinal-irradiation approach.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Also known as: COG ACNS0122
- Tags: soc-trials
- Registry id: NCT00047320
- Phase: 2
- Setting: Newly diagnosed central nervous system non-germinomatous germ cell tumours in children and young adults: six cycles of carboplatin, etoposide and ifosfamide, second-look surgery for residual disease, high-dose thiotepa and etoposide with stem cell rescue for poor responders, then craniospinal irradiation of 36 Gy with a boost
- Sponsor: Children's Oncology Group
- Enrolled: 104
- Result: 74 of 85 evaluable patients responded to induction chemotherapy; three-year progression-free survival 92 percent and overall survival 94.1 percent with craniospinal irradiation, the benchmark used by ACNS1123.
- Outcomes: Response to induction chemotherapy (registry results): Responders 74 participants vs Non-responders 11 participants; Progression-free survival at 3 years (as reported in the ACNS1123 comparison): Chemotherapy, second-look surgery, 36 Gy craniospinal irradiation with boost 92%; Overall survival at 3 years (as reported in the ACNS1123 comparison): Chemotherapy, second-look surgery, 36 Gy craniospinal irradiation with boost 94.1%

## Sources

- ClinicalTrials.gov NCT00047320: https://clinicaltrials.gov/study/NCT00047320

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/), [Central nervous system germ cell tumours (germinoma and non-germinomatous)](https://onco.cc/cancers/cns-germ-cell-tumours/), [Childhood cancers (all types)](https://onco.cc/cancers/childhood-cancers/)
- technologies: [Autologous stem cell transplant (high-dose therapy)](https://onco.cc/technologies/autologous-stem-cell-transplant/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Etoposide](https://onco.cc/drugs/etoposide/), [Ifosfamide](https://onco.cc/drugs/ifosfamide/), [Thiotepa](https://onco.cc/drugs/thiotepa/)
- institutions: [Children's Oncology Group (COG)](https://onco.cc/institutions/childrens-oncology-group/)
- key papers: [ACNS1123: response-based reduced radiotherapy for localised CNS non-germinomatous germ cell tumours](https://onco.cc/key-papers/paper-acns1123-nggct-reduced-radiotherapy-fangusaro-jco-2019/)

---
JSON: https://onco.cc/api/v1/entities/acns0122.json